Latest Conference Articles

Gail Wilensky PhD, senior fellow at Project HOPE, addresses the shift to value-based care over the years and what can be done to keep moving forward.

Thomas LeBlanc, MD, of the Duke Cancer Institute, discusses how palliative care has evolved over the past decade for patients with blood cancers.

Children's healthcare is more than just the Children's Health Insurance Program (CHIP). The area of children's health policy is one that is largely misunderstood, said Sara Rosenbaum, JD, the Harold and Jane Hirsh Professor of Health Law and Policy and founding chair of the Department of Health Policy at the Milken Institute School of Public Health, George Washington University.

Leigh Purvis, director of Health Services Research at AARP Public Policy Institute, discusses future policies that will relieve Medicare beneficiaries from some of their expensive out-of-pocket costs.

A clear majority of patients with cancer experience some sort of financial hardship, and the cost of care is something that weighs on the minds of patients and their families right from the moment of diagnosis, said Todd Yezefski, MD, senior fellow in the Clinical Research Division at the Fred Hutchinson Cancer Research Center and Division of Medical Oncology at the University of Washington.

Patients benefiting from federally qualified health centers tend to be sicker than the general population, but there are also disparities by state, explained M. Kristina Wharton, MPH, of the Department of Global Health Management and Policy at Tulane University School of Public Health and Tropical Medicine.

With more oncology patients receiving oral therapies, the pharmacist plays an important role in patient education and follow-up, said Stacey McCullough, PharmD, senior vice president of pharmacy at Tennessee Oncology.

mTOR is a very promising pathway because it’s so central in growth, migration, and survival of bladder cancer cells, explained Donna Hansel, MD, PhD, chief, anatomic pathology, UC San Diego.

On the closing day of the National Comprehensive Cancer Network (NCCN) 23rd Annual Conference in Orlando, Florida, Bijal Shah, MD, of Moffitt Cancer Center, presented on acute lymphoblastic leukemia (ALL), and on the lessons learned from the application of chimeric antigen receptor (CAR) T-cell therapy in this indication.

High costs in cancer care not only affects treatment outcomes for patients, but also their overall quality of life, explained Michele McCourt, senior director of the CancerCare Co-Payment Assistance Foundation.

Dan Klein, President and CEO, Patient Access Network Foundation, discusses how the lack of a limit on cost sharing in Medicare affects patient outcomes and disease states that PAN Foundation is keeping an eye on.

At the Society of Gynecologic Oncology’s 2018 Annual Meeting on Women’s Cancer, 1 abstract found Patient-Centered Oncology Payment model would yield savings if hospitalizations were reduced, while another abstract piloted a scoring system for financial toxicity in gynecological cancers.

The lead researcher said the study could lead to women being given a statin as soon as they are diagnosed with endometrial cancer.

Oliver Dorigo, MD, PhD, associate professor, obstetrics and gynecology, Stanford University Medical Center, discusses the use of PARP inhibitors and immunotherapy in gynecologic cancers.

William Cliby, MD, consultant, division of gynecologic surgery, department of obstetrics & gynecology, Mayo Clinic, discusses predictors of overall outcomes and survival in patients with ovarian cancer.

The use of immune checkpoint inhibitors has revolutionized the treatment of cancer, said John A. Thompson, MD, of the Fred Hutchinson Cancer Research Center and the Seattle Cancer Care Alliance, but “With this good news has come some not so good news”: immune-related adverse events can cause serious harm to patients receiving these drugs.

Much about using PARP inhibitors is open to debate, starting with what kind of genetic test to give before using them. Combination therapies are the next frontier, according to an expert panel.

Jim Schwartz, RPh, president of the National Community Oncology Dispensing Association and executive director of pharmacy operations for Texas Oncology, discusses how his practice will handle using CAR T-cell therapies to treat patients.

One in 5 parents of boys said the main reason that they haven’t vaccinated their sons for HPV was because they didn’t receive a recommendation for the vaccination, compared with 1 in 10 girls, said Anna Beavis, MD, MPH, a gynecologic oncologist fellow at Johns Hopkins University.

Approximately 60% of patients with endometrial cancer are obese, explained Victoria Bae-Jump, MD, PhD, associate professor, gynecologic oncology, University of North Carolina Lineberger Comprehensive Cancer Center.

Uptake for the human papillomavirus (HPV) vaccination has never reached CDC targets. Minority children from lower-income households are more likely to get the vaccination than white children from higher-income households, according to the study author.

An educational session helps oncologists understand the decision-making process for selecting treatments for recurrent ovarian cancer.

Having healthcare professionals with different sets of experiences or different training can help create better solutions and improve patient outcomes, explained Scott Page, PhD, the Leonid Hurwicz Collegiate Professor of Complex Systems, Political Science, and Economics at the University of Michigan.

Clinical trials, and offering patients support to take part in them, can extend lives of patients with ovarian cancer, according to a researcher from the Medical College of Georgia. But another analysis finds that gynecologial cancers are low on the government's funding priority list.

When making changes in healthcare, the patient’s voice is rarely at the table, said Martha Gaines, MD, JD, LLM, founder and director of The Center for Patient Partnerships, clinical professor of law, University of Wisconsin Law School.

Medicaid programs have been working to address to opioid epidemic in a number of ways and is starting to get involved in addressing social determinants of health, explained Anne L. Schwartz, PhD, executive director of the Medicaid and CHIP Payment and Access Commission.

At the National Comprehensive Cancer Network (NCCN) 23rd Annual Conference, held March 22-24 in Orlando, Florida, Sharon H. Giordano, MD, MPH, the University of Texas MD Anderson Cancer Center; Anthony D. Elias, MD, University of Colorado Cancer Center; and William J. Gradishar, MD, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, provided an update on the NCCN guidelines for the treatment of breast cancer and discussed new directions in breast cancer therapy.

During a Friday session of the National Comprehensive Cancer Network 23rd Annual Conference in Orlando, Florida, Cliff Goodman, PhD, of the Lewin Group, moderated a multi-stakeholder panel discussion on delivering and receiving cancer care in value-based care models.

The purpose of using Positive Quality Interventions (PQIs) is to create a more positive patient experience and better outcomes, explained Neal Dave, PharmD, pharmacy manager for Texas Oncology and chair of the PQI initiative for National Community Oncology Dispensing Association (NCODA).

The second day of the National Comprehensive Cancer Network (NCCN) 23rd Annual Conference in Orlando, Florida, opened with a dual keynote presentation on transforming cancer care in the United States.